Discover cutting-edge NGS in myeloid malignancy testing with insights from a leading Portuguese center. Join our free webinar on June 30, sponsored by @SOPHiAGENETICS. Register: hubs.li/Q04jXGkl0 #NGS #CancerTesting

PanTracer Pro ensures you have the insights tailored to your patient’s tumor type and clinical context needed to guide precision oncology: neogenomics.com/providers/on… #Oncology #PanTracerPro #NeoGenomics #CancerTesting

Diagnosing MDS is challenging because low blood counts can be caused by many non-cancer conditions. Neo Comprehensive® – Myeloid Disorders provides diagnostic precision and clarity: neogenomics.com/providers/te…. #Myeloid #Oncology #CancerTesting #MDSdiagnosis #BloodDisorders

Neo Comprehensive® – Myeloid Disorders, a CGP NGS assay, delivers clear and precise results for myeloid disorders, including MDS and CMML, helping clinicians make confident decisions. neogenomics.com/providers/te… #NeoGenomics #CancerTesting #OncologyInsights

Clinical Ambitions: 10x Expands Beyond Research with Trio of Collaborations With three new partnerships, @10xGenomics signals a move beyond research tools toward #clinicaldiagnostics using its single-cell and #spatialbiology platforms #cancertesting hubs.li/Q040vzDX0

Neo Comprehensive® – Myeloid Disorders, a CGP NGS assay, delivers clear and precise results for myeloid disorders, including MDS and CMML, helping clinicians make confident decisions. neogenomics.com/providers/te… #NeoGenomics #CancerTesting #OncologyInsights

Health Minister Motsoaledi says boosting NHLS staff and equipment could be more cost-effective than outsourcing, but requires extra funding to compete with private lab salaries and costs. #NHLS #HealthFunding #CancerTesting #PathCare #PublicHealth Read on tinyurl.com/u2jf25ay

Did you know? Up to 20% of breast tumors have higher levels of a protein known as HER2.¹ Browse our HER2 test offerings: neogenomics.com/test-menu/he… #HER2 #HER2Positive #BreastCancer #HER2Cancer #CancerTesting #Pathology 1: cancer.org/cancer/types/brea…

Home Cancer Tests Using Breath and Urine Get U.S. Funding Boost A U.S. federal health agency has awarded millions of dollars aimed at bringing cancer detection into the home @ARPA_H #cancertesting #OwlstoneMedicalLimited hubs.li/Q03MRSwT0

🩸 Every patient deserves access to lifesaving testing. But for many, access to early diagnosis depends on their insurance, ZIP code, or background. ✊ Let’s advocate for equity in testing, treatment, and outcomes. #CancerEquity #HealthJustice #HealthEquity #CancerTesting

AI-Powered Oncology and Genomic Testing Converge with VieCure and Guardant Healthcare Partnership @VieCure's partnership with @GuardantHealth consolidates liquid and tissue-based diagnostics #cancertesting #EHR #liquidbiopsy hubs.li/Q03wXBwq0

⏯️ Check out this new video showing the ability of NeXT Personal® to consistently achieve highly sensitive limits of detection (LOD) across a large number of patient samples across many solid tumor types, including samples of poor quality: • NeXT Personal demonstrated a median LOD of 1.9 parts per million (PPM) with a range of 1.6-2.8 PPM across this real world data cohort (4,232 plasma timepoints across 1,796 patients) • 40.9% of all MRD positive samples were detected in the ultrasensitive range (≤100 PPM), and 86.8% of molecular recurrence detections were in the ultrasensitive range • Median ctDNA level for first molecular recurrence detection was 12 PPM, underscoring the importance of ultrasensitive testing for early recurrence detection #PrecisionOncology #ctDNA #SensitivityMatters #MRD #LiquidBiopsy #CancerTesting

#ColorectalCancerAwarenessMonth may be drawing to a close, but the conversation should continue all year long. We look forward to supporting your patient care with comprehensive solutions: neogenomics.com/providers/on… #CancerTesting #Pathologist #Oncologist

The Immuno-Oncology 360° Summit began today at the Sheraton Boston in Massachusetts. Our experts are on-site at booth #7, ready to discuss innovative testing solutions to advance oncology drug development. #Boston #NeoGenomics #CancerTesting #Oncology #ImmunoOncology #IO360

#ColorectalCancerMonth begins today. Follow us as we highlight testing solutions, share resources, and more each week. #ColonCancerAwarenessMonth #CRC #CRCMonth #CancerTesting #Oncology

“Minimal residual disease (#MRD) #CancerTesting is becoming an increasingly essential part of patient management, as studies show it benefits patients. It enables medical teams to make earlier and more informed decisions in the recovery stages. This shift from reactive to proactive care reduces guesswork and helps provide better peace of mind for patients worried about their #cancer returning.” Read more from Richard Chen, MD, MS, Chief Medical Officer and EVP of R&D at Personalis on his thoughts on advances in #PersonalizedMedicine reshaping patient care: bit.ly/419zytD. #PrecisionOncology #ctDNA

During #CervicalCancer Awareness Month, we’re shining a spotlight on testing solutions to support your therapy decisions, prognosis, and clinical research. #CancerTesting #Oncology #CervicalCancerAwarenessMonth

(FOX NEWS) - "The year in cancer: Advances made in 2024, predictions for 2025." #CancerRisk #CancerTesting #CancerPatients #ProcessedFoods #ColonCancer #CancerStudies #HarmsOfProcessedFoods #RiskForColonCancer #CancerExperts #HarmsInFastFoods #Oncologists foxnews.com/health/year-canc…

What questions should #endometrialcancer patients ask about #endometrialcancer testing? Insights from Dr. Emily Hinchcliff @hinchcliffemily of @NorthwesternMed ow.ly/alRl50UlHMc #gyncsm #endometrialcancerawareness #cancer #cancertesting

#LungCancerAwarenessMonth begins today! Each year, we use this special time to share education and resources, support survivors, highlight testing solutions, and more. #LungCancerAwarenessMonth #LungCancerAwareness2024 #CancerTesting #Oncology #NeoGenomics